Your new experience awaits. Try the new design now and help us make it even better

CASE REPORT article

Front. Med.

Sec. Intensive Care Medicine and Anesthesiology

Volume 12 - 2025 | doi: 10.3389/fmed.2025.1599413

This article is part of the Research TopicTesticular Cancer Awareness Month 2025: Spotlighting Advances in Research and Treatment for Testicular Cancer PatientsView all articles

Salvage chemotherapy in the intensive care unit: a case report of successful treatment of a critically ill patient with metastatic testicular germ cell tumor

Provisionally accepted
Karol  GrelaKarol Grela*Mikołaj  SobczyńskiMikołaj SobczyńskiMateusz  PiętakMateusz PiętakBarbara  KruczykBarbara KruczykPiotr  DomańskiPiotr DomańskiJakub  KucharzJakub KucharzMałgorzata  SymonidesMałgorzata SymonidesTomasz  DemkowTomasz Demkow
  • Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland

The final, formatted version of the article will be published soon.

Testicular cancer, predominant among young males, poses a significant healthcare challenge with varying incidence rates across European regions. Germ cell tumors (GCTs), constituting 95% of the cases, can be divided into seminoma and nonseminomatous germ cell tumors (NSGCTs). Metastases commonly occur in the lungs, lymph nodes, liver, bone, and brain. This study focuses on a 23-year-old with metastatic NSGCT, who underwent chemotherapy in an intensive care unit setting, followed by a remarkable improvement in his condition.The patient's initial complaint was persistent abdominal pain, which led to a discovery of an extensive tumor in the abdominal cavity. He underwent cytoreductive surgery, and required admission to an intensive care unit (ICU) due to surgical complications.Histopathology identified a yolk sac tumor. Despite the serious condition, chemotherapy was started. The patient's condition continued to deteriorate, requiring the initiation of mechanical ventilation. However, the multidisciplinary team opted for a continued treatment. Eventually, the AFP levels started to decrease and a gradual improvement of the patient's condition have been observed. This allowed to a bleomycin, etoposide, and platinum regimen. Following a complex hospitalization and subsequent surgical resection of residual lesions, the patient remains in good clinical condition. Regular follow-up evaluations have revealed no evidence of disease recurrence.Although NSGCT is characterized by a rather favorable prognosis, it is a significant challenge to clinicians, as the diagnosis is often delayed due to the lack or low specificity of the symptoms. Despite the usually young age of the patients diagnosed with metastatic NSGCT, the patients condition can deteriorate rapidly, presenting with multiorgan failure and a need for an ICU treatment. However, the severity of the patients' condition should not be unequivocally associated with being not suitable for a systemic curative treatment. Such patients can still benefit from the chemotherapy, and a cooperation between the oncologists and critical care physicians is crucial to improving the outcomes and increase the probability of recovery.

Keywords: testicular cancer, Germ cell tumor, Intensive Care Unit, chemotherapy, Dialysis

Received: 24 Mar 2025; Accepted: 28 May 2025.

Copyright: © 2025 Grela, Sobczyński, Piętak, Kruczyk, Domański, Kucharz, Symonides and Demkow. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Karol Grela, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.